Rapid response with ketamine on suicidal cognition in resistant depression

Rajarshi Guha Thakurta, Ranjan Das, Amit Kumar Bhattacharya, Debasish Saha, Sreyashi Sen, Om Prakash Singh, Bikash Bisui, Rajarshi Guha Thakurta, Ranjan Das, Amit Kumar Bhattacharya, Debasish Saha, Sreyashi Sen, Om Prakash Singh, Bikash Bisui

Abstract

Context: Suicidal ideation in depressed patients is a serious and emergent condition that requires urgent intervention. Intravenous ketamine, an N-methyl-D-aspartate (NMDA) antagonist, has shown rapid antidepressant effects, making it a potentially attractive candidate for depressed patients with suicidal risk.

Aims: In India few studies have corroborated such findings; the present study aimed to assess the effectiveness and sustainability of antisuicidal effects of ketamine in subjects with resistant depression.

Settings and design: Single-center, prospective, 4 weeks, open-label, single-arm pilot study.

Materials and methods: Twenty-seven subjects with DSM-IV major depression (treatment resistant) were recruited. The subjects were assessed on Scale for Suicidal Ideation (SSI), 17-item Hamilton Depression Rating Scale (HDRS). After a 2-week drug-free period, subjects were given a single intravenous infusion of ketamine hydrochloride (0.5 mg/kg) and were rated at baseline and at 40, 80, 120, and 230 minutes and 1 and 2 days postinfusion.

Results: The ketamine infusion was effective in reducing the SSI and HDRS scores, the change remained significant from minute 40 to 230 at each time point.

Conclusions: The real strength of this study rests in documenting the rapid albeit short-lasting effect of ketamine on suicidal ideation in depressed patients.

Keywords: Glutamate; ketamine; suicidal cognition; treatment-resistant depression.

Conflict of interest statement

Conflict of Interest: None.

Figures

Figure 1
Figure 1
The change in the mean SSI score scores over time, †P<0.01, ‡P<0.001
Figure 2
Figure 2
The change in the mean HDRS SI scores over time, †P<0.01, ‡P<0.001
Figure 3
Figure 3
The change in the mean HDRS scores over time, †P<0.01, ‡P<0.001
Figure 4
Figure 4
The change in the mean BPRS scores over time, ‡P<0.001

References

    1. Claassen CA, Trivedi MH, Rush AJ, Husain MM, Zisook S, Young E, et al. Clinical differences among depressed patients with and without a history of suicide attempts: Findings from the STAR*D trial. J Affect Disord. 2007;97:77–84.
    1. Deisenhammer EA, Ing CM, Strauss R, Kemmler G, Hinterhuber H, Weiss EM. The duration of the suicidal process: How much time is left for intervention between consideration and accomplishment of a suicide attempt? J Clin Psychiatry. 2009;70:19–24.
    1. Hunt IM, Kapur N, Webb R, Robinson J, Burns J, Shaw J, et al. Suicide in recently discharged psychiatric patients: A case-control study. Psychol Med. 2009;39:443–9.
    1. Janofsky JS. Reducing inpatient suicide risk: Using human factors analysis to improve observation practices. J Am Acad Psychiatry Law. 2009;37:15–24.
    1. Mills PD, DeRosier JM, Ballot BA, Shepherd M, Bagian JP. Inpatient suicide and suicide attempts in Veterans Affairs hospitals. Jt Comm J Qual Patient Saf. 2008;34:482–8.
    1. Yeager KR Y, Saveanu R, Robers AR, et al. Measured response to identified suicide risk and violence: what you need to know about psychiatric patient safety. Brief Treat Crisis Interven. 2005;5:121–141. (text book)
    1. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA. 2004;292:338–43.
    1. Kellner CH, Fink M, Knapp R, Petrides G, Husain M, Rummans T, et al. Relief of expressed suicidal intent by ECT: A consortium for research in ECT study. Am J Psychiatry. 2005;162:977–82.
    1. Szanto K, Mulsant BH, Houck P, Dew MA, Reynolds CF., 3rd Occurrence and course of suicidality during short-term treatment of late-life depression. Arch Gen Psychiatry. 2003;60:610–7.
    1. Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J. Decreased risk of suicides and suicide attempts during long-term lithium treatment: A meta-analytic review. Bipolar Disord. 2006;8:625–39.
    1. Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ. Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry. 2007;68:380–3.
    1. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT) Arch Gen Psychiatry. 2003;60:82–91.
    1. Mathew SJ, Murrough JW, Aan Het Rot M, Collins KA, Reich DL, Charney DS. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: A pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol. 2010;13:71–82.
    1. Ernst CL, Goldberg JF. Antisuicide properties of psychotropic drugs: A critical review. Harv Rev Psychiatry. 2004;12:14–41.
    1. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62(Suppl 16):10–7.
    1. First MB, Spitzer RL, Gibbon M, Williams AR. Structured clinical interview for DSM-IV TR Axis I disorders, research version, patient edition (SCID-I/P) New York: New York State Psychiatric Institute, Biometrics Research; 2001.
    1. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.
    1. Beck AT, Kovacs M, Weissman A. Assessment of suicidal intention: The scale for suicide Ideation. J Consult Clin Psychol. 1979;47:343–52.
    1. Holi MM, Pelkonen M, Karlsson L, Kiviruusu O, Ruuttu T, Heilä H, et al. Psychometric properties and clinical utility of the Scale for Suicidal Ideation (SSI) in adolescents. BMC Psychiatry. 2005;5:8.
    1. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962;10:799–812.
    1. Reeves H, Batra S, May RS, Zhang R, Dahl DC, Li X. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: A randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2008;69:1228–336.
    1. Patel M, Patel S, Hardy DW, Benzies BJ, Tare V. Should electroconvulsive therapy be an early consideration for suicidal patients? J ECT. 2006;22:113–5.
    1. DiazGranados N, Ibrahim LA, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DA, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry. 2010;71:1605–11.
    1. Zarate CA, Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856–64.
    1. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997;17:2921–7.
    1. Maeng S, Zarate CA, Jr, Du J, Schloesser RJ, McCammon J, Chen G, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2008;63:349–52.
    1. White PF, Schuttler J, Shafer A, Stanski DR, Horai Y, Trevor AJ. Comparative pharmacology of the ketamine isomers: Studies in volunteers. Br J Anaesth. 1985;57:197–203.
    1. Rao TS, Andrade C. Innovative approaches to treatment- refractory depression: The ketamine story. Indian J Psychiatry. 2010;52:97–9.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever